Czirr James C's Form 4/A amendment
AmendedGalectin Therapeutics IncGALT · filed Dec 8, 2025
- Accession no.
- 0001493152-25-026587
- Filed
- Dec 8, 2025, 1:21 PM ET
- Trade date
- Dec 2-3, 2025
- Filing delay
- 6 days
- Rule 10b5-1 plan
- Not checked
- Original filed
- Dec 4, 2025
This filing lists 2 non-derivative transactions. Open-market sales total $920.9K. It was filed 6 days after the trade.
This amendment replaces 0001493152-25-026204 (filed Dec 4, 2025).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Czirr James CCIK 0001260641 | 10% Owner |
| 10X Fund, L.P.CIK 0001453356 | 10% Owner |
| 10X Capital Management, LLCCIK 0001457247 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
- F2
The shares were sold in multiple transactions at prices ranging from $5.40 to $5.50. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
Referenced by the price of 1 transaction in Table I.
- F3
The shares were sold in multiple transactions at prices ranging from $5.68 to $5.85. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
Referenced by the price of 1 transaction in Table I.